Compare DNN & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNN | GLPG |
|---|---|---|
| Founded | 1954 | 1999 |
| Country | Canada | Belgium |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 1997 | 2005 |
| Metric | DNN | GLPG |
|---|---|---|
| Price | $2.63 | $32.59 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | ★ 39.5M | 90.2K |
| Earning Date | 11-06-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,493,456.00 | ★ $336,643,201.00 |
| Revenue This Year | $197.29 | $1.76 |
| Revenue Next Year | $55.12 | $0.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.35 | 10.31 |
| 52 Week Low | $1.08 | $22.36 |
| 52 Week High | $3.42 | $37.78 |
| Indicator | DNN | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 48.67 | 56.99 |
| Support Level | $2.48 | $32.65 |
| Resistance Level | $2.81 | $33.23 |
| Average True Range (ATR) | 0.15 | 0.63 |
| MACD | 0.00 | 0.14 |
| Stochastic Oscillator | 37.80 | 73.16 |
Denison Mines Corp is a uranium exploration and development company focused on the Athabasca Basin region of northern Saskatchewan, Canada. The company holds a noteworthy 95% interest in its flagship Wheeler River Uranium Project, the undeveloped uranium project located in the infrastructure-rich eastern part of the Athabasca Basin. Additionally, it is involved in mine decommissioning and environmental services through its Closed Mines group, which manages the Elliot Lake reclamation projects and offers third-party post-closure mine care and maintenance services. The Company operates in two main segments: the Mining segment and the Corporate and Other segment. The majority of revenue is generated from the mining segment.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.